Boehringer Ingelheim says it is pleased with Mirapexin recommendation

Boehringer Ingelheim is pleased about the recommendation Mirapexin/ Sifrol (pramipexole) has received.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted the drug – which is intended to help treat the signs and symptoms of idiopathic Parkinson’s disease ? a positive opinion.

It has suggested the once daily formulation should be approved in all EU countries, as well as Norway, Iceland and Liechtenstein.

Dr Manfred Haehl is the senior vice-president of the company’s medicine department and explained the drug has been found to cause fewer pramipexole plasma fluctuations compared to the three-times daily administered pramipexole.

Once the drug is approved, patients may be switched overnight from the immediate release medication to the new extended release one, he added, noting it would be more convenient for them because they only have to take a single pill.

“It is important for physicians to have effective and flexible treatment regimens to choose from so that they can offer individualised treatments in line with the patient’s needs,” stated Mr Haehl.

Earlier this month, Boehringer Ingelheim discussed results from an ambulatory blood pressure study, which tested telmisartan at very high altitude levels.